The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Market Size Is Forecasted For The Myelodysplastic Syndrome (MDS) Drugs Market By 2030 Based On Its 2026 Value?
The myelodysplastic syndrome (mds) drugs market size has demonstrated robust growth in recent years. It is projected to increase from $3.7 billion in 2025 to $3.98 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.6%. The expansion observed in the historic period can be ascribed to several factors, including increasing diagnosis rates of bone marrow disorders, the availability of hypomethylating agents, the continued expansion of oncology treatment centers, a rising utilization of supportive transfusion therapies, and improved awareness of the disease.
The myelodysplastic syndrome (mds) drugs market size is projected for substantial expansion over the upcoming years. It is anticipated to reach $5.56 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 8.7%. This expansion during the forecast period can be primarily attributed to the increasing development of novel immunomodulatory drugs, the rising adoption of precision medicine in hematology, the expansion of clinical trial pipelines, a growing focus on improving patient quality of life, and increasing healthcare spending on rare diseases. Furthermore, major trends in the forecast period include the increasing use of targeted therapeutic regimens, the rising adoption of oral and parenteral combination therapies, a growing focus on personalized treatment approaches, the expansion of supportive care therapies, and enhanced monitoring of treatment outcomes.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13043&type=smp
Which Strategic Drivers Are Supporting The Myelodysplastic Syndrome (MDS) Drugs Market Development?
The rising prevalence of myeloid leukemia is anticipated to boost the expansion of the myelodysplastic syndrome (MDS) drug treatment market in the future. Myeloid leukemia is a form of cancer that begins in the bone marrow, impacting cells responsible for generating different types of blood cells. Myelodysplastic syndrome (MDS) drugs are designed to enhance bone marrow function by addressing the underlying cause of leukemia, thereby mitigating the risk of complications from low blood cell counts, lessening the reliance on chemotherapy and transplants, and enhancing survival rates for individuals with myelodysplastic syndrome (MDS) drugs. For example, in January 2023, the American Cancer Society, a US-based voluntary health organization, estimated approximately 20,380 cases and 11,310 deaths of acute myeloid leukemia (AML) would occur in adults during 2023. Consequently, the growing frequency of myeloid leukemia cases is fueling the myelodysplastic syndrome (MDS) drug market. The increasing investment in research and development is projected to boost the expansion of the myelodysplastic syndrome (MDS) drugs market moving forward. Research and development encompasses systematic scientific inquiry and experimental efforts focused on discovering, developing, and refining new therapeutic agents and treatment methodologies. This increase in R&D stems from an enhanced understanding of MDS’s molecular origins and genetic mutations, allowing pharmaceutical companies and research institutions to pinpoint novel therapeutic targets and devise precision medicine strategies for this diverse condition. Elevated research and development directly fuels market growth by broadening the range of investigational therapies, resulting in new drug approvals that offer additional treatment avenues for patients unresponsive to standard hypomethylating agent therapy or requiring alternative interventions. For instance, in February 2025, the National Center for Science and Engineering Statistics (NCSES), a US-based government statistical agency, reported that U.S. research and development expenditures grew from $892 billion in 2022 to $940 billion in 2023, representing a $48 billion rise. Thus, heightened research and development activities are propelling the growth of the myelodysplastic syndrome (MDS) drugs market.
How Is Segment Classification Applied In The Myelodysplastic Syndrome (MDS) Drugs Market?
The myelodysplastic syndrome (mds) drugs market covered in this report is segmented –
1) By Drug Type: Chemotherapy, Immunomodulatory Drugs
2) By Route Of Administration: Oral, Parenteral
3) By Syndrome: Refractory Cytopenia With Multilineage Dysplasia, Refractory Anemia, Refractory Anemia With Ringed Sideroblasts
4) By End User: Hospitals, Clinics, Ambulatory Surgical Centers
Subsegments:
1) By Chemotherapy: Hypomethylating Agents, Cytotoxic Agents
2) By Immunomodulatory Drugs: Lenalidomide, Thalidomide, Pomalidomide
What Trends Are Shaping The Myelodysplastic Syndrome (MDS) Drugs Market Structure?
Leading companies within the myelodysplastic syndrome (MDS) drugs market are primarily focused on developing novel products, such as targeted therapy, to enhance patient outcomes, fulfill specific customer demands, and seamlessly integrate into the existing healthcare environment. Targeted therapy for myelodysplastic syndromes (MDS) involves the application of drugs specifically engineered to identify and act upon genetic mutations or molecular anomalies present in cancer cells. The objective is to improve patient results by selectively eradicating abnormal cells while minimizing damage to healthy tissues. For instance, in October 2023, the U.S. Food and Drug Administration (FDA) approved Tibsovo (ivosidenib) for treating adult patients suffering from relapsed or refractory (R/R) myelodysplastic syndromes (MDS) linked to an isocitrate dehydrogenase-1 (IDH1) mutation. The effectiveness of Tibsovo for this new therapeutic indication was assessed in an open-label, single-arm, multicenter investigation involving 18 adult patients with relapsed or refractory MDS who carried an IDH1 mutation.
Which Companies Are Engaged In The Myelodysplastic Syndrome (MDS) Drugs Market Environment?
Major companies operating in the myelodysplastic syndrome (mds) drugs market are Bristol Myers Squibb, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Mylan NV, Cipla Limited, Acceleron Pharma Inc., Aprea Therapeutics, Onconova Therapeutics Inc., Geron Corporation, Amgen Inc., Sandoz, Gilead Sciences Inc., Johnson And Johnson, Lupin Ltd. Corporation, Ono Pharmaceutical Co. Ltd., Eisai Co. Ltd., Nippon Shinyaku Co. Ltd., Lupin Ltd., Accord Healthcare Inc., Kite Pharma Inc., Karyopharm Therapeutics Inc., Aprea Therapeutics Inc., Acceleron Pharma Inc., Astex Pharmaceuticals Inc., Stemline Therapeutics Inc., Geron Corporation, Onconova Therapeutics Inc., Actinium Pharmaceuticals Inc., Millennium Pharmaceuticals Inc.
Access The Complete Myelodysplastic Syndrome (MDS) Drugs Market Report:
Which Regional Market Leads The Myelodysplastic Syndrome (MDS) Drugs Market?
North America was the largest region in the myelodysplastic syndrome (MDS) drugs market in 2025. The regions covered in the myelodysplastic syndrome (mds) drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Myelodysplastic Syndrome (MDS) Drugs Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=13043&type=smp
Browse Through More Reports Similar to the Global Myelodysplastic Syndrome (MDS) Drugs Market 2026, By The Business Research Company
Bone Marrow Transplantation Market Report 2026
https://www.thebusinessresearchcompany.com/report/bone-marrow-transplantation-global-market-report
Blood Transfusion Diagnostics Market Report 2026
https://www.thebusinessresearchcompany.com/report/blood-transfusion-diagnostics-global-market-report
Patient Blood Management Market Report 2026
https://www.thebusinessresearchcompany.com/report/patient-blood-management-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model